The advent of targeted therapies generated much optimism when discovered. Targeted therapies, are however associated with rapid acquisition of resistance. In a recent study by Dong et al. (Theranostics 2018; 8(7):1808-1823. doi:10.7150/thno.23177) it was shown that lung tumors resistant to the EGFR-inhibitor (Erlotinib), reprogram their metabolism and acquire a pro-survival dependency on Phosphoglycerate Dehydrogenase (PHGDH) that can be targeted to eliminate resistant tumors.

中文翻译：

---

抵抗靶向治疗-代谢负债的目标

被发现时，靶向疗法的出现使人们非常乐观。然而，靶向治疗与耐药性的快速获得有关。在Dong等人的最新研究中。（Theranostics 2018; 8（7）：1808-1823。doi：10.7150 / thno.23177）已显示对EGFR抑制剂（Erlotinib）有抗性的肺肿瘤，重新编程其代谢并获得对磷酸甘油酸脱氢酶的生存前依赖性（PHGDH）可以靶向消除耐药性肿瘤。